Kush P Patel, Alexandra J Lansky, Henning Kelbæk, Bo Xu, Niels van Royen, Thomas W Johnson, Richard Anderson, William Wijns, Andreas Baumbach
In the TARGET All Comers trial, the biodegradable-polymer sirolimus-eluting FIREHAWK stent (BP SES) was non-inferior to the durable-polymer everolimus-eluting XIENCE stent (DP EES) with respect to target lesion failure (TLF) at 1 and 5 years; however, long-term safety and efficacy in the setting of acute coronary syndromes (ACS) are not known. We sought to assess the long-term outcomes in ACS vs chronic coronary syndromes (CCS) with BP SES vs DP EES. The TARGET AC study was a multicenter, open-label, noninferiority trial of all comer patients randomized 1:1 to BP SES or DP EES (stratified by ST-elevation myocardial infarction and study site)...
February 11, 2024: American Journal of Cardiology